Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.

Item
http://www.wikidata.org/entity/Q33744839
Manipulating regulatory T cells: a promising strategy to treat autoimmunityRegulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialProtocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studyHuman IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment.Strategies for clinical trials in type 1 diabetesProgress and challenges for treating Type 1 diabetes.Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.New Insights and Biomarkers for Type 1 Diabetes: Review for Scandinavian Journal of Immunology.Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?Dominant TNFα and impaired IL-2 cytokine profiles of CD4+ T cells from children with type-1 diabetes.Adaptive designs in clinical trials: why use them, and how to run and report them.
P2860

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.

Item
http://www.wikidata.org/entity/Q33744839
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rationale and study design of ...... , adaptive dose finding trial.
@ast
Rationale and study design of ...... , adaptive dose finding trial.
@en
type
label
Rationale and study design of ...... , adaptive dose finding trial.
@ast
Rationale and study design of ...... , adaptive dose finding trial.
@en
prefLabel
Rationale and study design of ...... , adaptive dose finding trial.
@ast
Rationale and study design of ...... , adaptive dose finding trial.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Rationale and study design of ...... , adaptive dose finding trial.
@en
P2093
P2860
P304
P31
P356
10.1136/BMJOPEN-2014-005559
P433
P478
P50
P577
P5875
P698
P921
P932